|description=FDA-approved first-line chemotherapy for unresectable pleural mesothelioma. EMP
...10px; font-weight:bold; width:45%; border-bottom:1px solid #dee2e6;" | FDA approval
...
6 KB (734 words) - 14:18, 21 May 2026
...ioma immunotherapy, nivolumab ipilimumab, mesothelioma clinical trial, FDA approval 2020, Dr. Paul Baas, mesothelioma treatment
...e="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA Approval
...
21 KB (2,649 words) - 23:25, 14 May 2026
...helioma research milestones from 1767 discovery through 2020 immunotherapy approval to current CAR-T and gene therapy research.
...imeline, mesothelioma history, asbestos cancer history, CheckMate 743, FDA approval mesothelioma, mesothelioma research milestones
...
20 KB (2,497 words) - 23:25, 14 May 2026
|title=Mesothelioma Immunotherapy: FDA-Approved Drugs and Effectiveness
...othelioma, pembrolizumab mesothelioma, CheckMate 743, IND227, KEYNOTE-483, FDA approved mesothelioma drugs, checkpoint inhibitor mesothelioma, PD-1 mesoth
...
24 KB (2,899 words) - 23:07, 14 May 2026
...doubled from 8.8 months to 18.1 months. These findings led directly to FDA approval in October 2020, transforming treatment options for mesothelioma patients w
| style="padding:10px;" | FDA Approval Date
...
28 KB (3,537 words) - 23:25, 14 May 2026
...t established immunotherapy as the new standard of care in 2020.<ref name="fda-nivo-ipi" /> Today, researchers are exploring CAR-T cell therapy, gene ther
...months or longer with modern multimodal treatment approaches. The 2020 FDA approval of nivolumab plus ipilimumab marked the first new systemic therapy for meso
...
38 KB (4,762 words) - 23:25, 14 May 2026
= Mesothelioma Treatment Options and Costs: 4 FDA-Approved Therapies, 53+ Active Clinical Trials, $100,000-$400,000 Annual Ex
...line nivolumab plus ipilimumab in the CheckMate 743 5-year follow-up. Four FDA-approved treatment pathways exist as of 2026: traditional chemotherapy, imm
...
38 KB (4,508 words) - 14:24, 21 May 2026
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA Approved
...apy backbone for epithelioid disease.<ref name="emphacis" /><ref name="fda-approval" /> Although dual immune checkpoint blockade with nivolumab plus ipilimumab
...
48 KB (5,868 words) - 23:25, 14 May 2026
|title=TTFields / Optune Lua for Mesothelioma: STELLAR Trial, FDA HDE Approval & 2026 Treatment Guide
...mesothelioma. Covers STELLAR final results (18.2-month median OS), FDA HDE approval (no PMA), TIGER Meso registry, NCCN/ASCO guideline status, mechanism of act
...
73 KB (9,572 words) - 17:52, 20 May 2026
|title=Immunotherapy for Mesothelioma: CheckMate 743, Clinical Trials & FDA-Approved Treatment
...ve guide to immunotherapy for malignant pleural mesothelioma including the FDA-approved nivolumab plus ipilimumab combination, CheckMate 743 trial results
...
63 KB (8,147 words) - 05:05, 25 May 2026
| style="padding:8px 10px; background:#f8f9fa; font-weight:bold;" | FDA-approved serum biomarker
| style="padding:8px 10px;" | SpindleMesoNET AUC 0.989; MesoNet validated; no FDA-cleared mesothelioma-specific tool
...
39 KB (4,780 words) - 23:07, 14 May 2026
...-support tool; not yet standard of care; not Food and Drug Administration (FDA)-cleared as a companion diagnostic; not covered by Medicare or private insu
...e checkpoint inhibitor regimens:''' nivolumab + ipilimumab (CheckMate 743, FDA-approved first-line October 2020) and pembrolizumab + pemetrexed/platinum c
...
36 KB (4,576 words) - 21:55, 25 May 2026
...hensive guide to blood test early detection for mesothelioma including the FDA-approved MESOMARK assay, SOMAmer 13-protein panel, calretinin prediagnostic
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved Test
...
39 KB (5,126 words) - 23:25, 14 May 2026
...mprehensive guide to blood-based biomarkers for mesothelioma including the FDA-approved MESOMARK assay, fibulin-3, osteopontin, HMGB1, SOMAmer panel, and
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved Test
...
38 KB (4,854 words) - 23:25, 14 May 2026
...ioma|Immunotherapy]] drugs including nivolumab and ipilimumab received FDA approval for unresectable mesothelioma and have shown improved survival.<ref name="i
...
11 KB (1,460 words) - 05:05, 25 May 2026
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved Regimens
...roves Pembrolizumab with Chemotherapy for Malignant Pleural Mesothelioma], FDA.gov, September 2024</ref> The most significant recent milestone is the Chec
...
111 KB (14,507 words) - 23:25, 14 May 2026
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved Regimens
...arginine depletion therapy (BLA under FDA review), tumor treating fields (FDA-approved under Humanitarian Device Exemption), and mesothelin-targeted CAR-
...
55 KB (6,941 words) - 05:05, 25 May 2026
...over the course of treatment.<ref name="pmc6637828" /> Since the 2020 FDA approval of immunotherapy (Opdivo + Yervoy) as a first-line treatment, average per-p
...
14 KB (1,832 words) - 05:05, 25 May 2026
...edian survival of 12–21 months using multimodal therapy including the 2020 FDA-approved nivolumab plus ipilimumab<ref name="mlcpleural" />
* '''Immunotherapy:''' Opdivo (nivolumab) plus Yervoy (ipilimumab) FDA-approved 2020
...
28 KB (3,459 words) - 13:51, 23 May 2026
| '''Mesothelin Biomarker Accuracy''' || 61% sensitivity, 87% specificity; FDA-approved diagnostic marker<ref name="biomarkerdata" />
...' || Immunotherapy median OS 18.1 months vs. 14.1 months for chemotherapy; FDA approved October 2020<ref name="checkmate743" />
...
43 KB (5,359 words) - 23:24, 14 May 2026
